Making genetic test results clearer using large-scale lab evidence
Platform to support clinical variant interpretation through probabilistic assessment of functional evidence
This project builds a tool that helps doctors and labs use high-throughput lab experiments to clarify whether genetic changes are likely harmful for people with inherited disease risks.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Constantiam Biosciences INC. NIH-funded |
| Lab location | 1 site (Katy, United States) |
| Project ID | NIH-11101135 on NIH RePORTER |
What this research studies
If you or a family member got a genetic test that reported a variant of uncertain significance (VUS), this project aims to speed up and standardize how those unclear results are interpreted. The team curates and combines data from Multiplexed Assays of Variant Effect (MAVEs), which test thousands of genetic changes in a single experiment, and uses probabilistic models to turn complex functional data into clinical evidence. The platform, called Varify, is designed to reduce the manual, error-prone work genetic testing labs now do and to provide clear, reproducible guidance for variant classification. Ultimately it aims to feed more reliable functional evidence into the reports clinicians and patients receive.
Who could benefit from this research
Good fit: People who received genetic testing that reported a variant of uncertain significance in genes linked to inherited cancers or other genetic conditions (for example BRCA1/2, TP53, BRAF) are the most relevant group.
Not a fit: People without genetic test findings or those whose variants are already clearly classified as benign or pathogenic are unlikely to benefit directly from this platform.
Why it matters
Potential benefit: If successful, this could reduce the number of uncertain genetic test results and help people get clearer diagnoses and treatment guidance faster.
How similar studies have performed: Large-scale functional assays (MAVEs) have already helped reclassify many VUSs—studies report reclassification of roughly 44% of VUS within genes that have been assayed—while commercial platforms to integrate these data are still emerging.
Where this research is happening
Katy, United States
- Constantiam Biosciences INC. — Katy, United States (Active)
Researchers
- Principal investigator: Schafer, Nicholas — Constantiam Biosciences INC.
- Study coordinator: Schafer, Nicholas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.